Crinetics Pharmaceuticals Inc diskutieren
Crinetics Pharmaceuticals Inc
WKN: A2JQTJ / Symbol: CRNX / Name: Crinetics Pharmaceuticals / Aktie / Small Cap /
41,40 €
0,49 %
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Evercore ISI from $41.00 to $48.00. They now have an "outperform" rating on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Robert W. Baird from $43.00 to $45.00. They now have an "outperform" rating on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $40.00 to $46.00. They now have an "outperform" rating on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock, down previously from $52.00.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $35.00 price target on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $42.00 price target on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Robert W. Baird from $45.00 to $52.00. They now have an "outperform" rating on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $46.00 to $48.00. They now have an "outperform" rating on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Cantor Fitzgerald from $50.00 to $65.00. They now have an "overweight" rating on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $54.00 price target on the stock, up previously from $48.00.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Ratings data for CRNX provided by MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Jonestrading from $52.00 to $56.00. They now have a "buy" rating on the stock.
Ratings data for CRNX provided by MarketBeat
Neueste Beiträge
Cantor_Fitzgerald in Insmed Inc. diskutieren